Simplified global trading solutions designed for speed, transparency.
↳
With deep industry expertise and a strong global network, we manage sourcing, logistics, and compliance with precision.
Blogs
Explore insights, trends, and ideas in branding, marketing, design, and digital growth. Stay updated with practical strategies, creative inspiration, and industry knowledge to help your business grow smarter and stronger.
19.06.2026 Insights
How Indian Pharmaceutical Exporters Are Powering Global Healthcare Supply Chains
Every time a pharmacist in London dispenses a generic antibiotic, or a hospital in Nairobi administers a vaccine, there is a good chance the medicine came from India. The numbers behind that statement are staggering, and they keep growing. India’s pharmaceutical exports crossed USD 30.47 billion in FY 2024-25, a 9.4% year-on-year increase driven by strong global demand and a manufacturing base that few countries can match.
Let’s break it down.
Why India Became the World's Pharmacy
India did not stumble into this position. Decades of investment in chemistry education, government support for generic drug manufacturing, and a competitive cost structure built a pharmaceutical sector that now ranks third globally by production volume.
Here is why the numbers matter:
- Indian drugs ship to more than 200 countries, with approximately 70% of exports destined for highly regulated markets in North America and Europe.
- India supplies 40% of generic drug demand in the United States and 25% of all medicines in the United Kingdom.
- The country produces over 60% of the world’s vaccines by volume and meets 99% of WHO’s demand for DPT vaccines.
- Indian firms supply over 80% of antiretroviral drugs used globally to combat HIV/AIDS.
Indian manufacturers compete on price while holding regulatory approvals from the US FDA, the European Medicines Agency (EMA), and the WHO, a combination that buyers in developed markets find difficult to replicate from other sources.
The Active Pharmaceutical Ingredient Backbone
Finished tablets and capsules get most of the attention, but the real story of Indian pharmaceutical exporters runs deeper. Active Pharmaceutical Ingredients (APIs) are the biologically active compounds that give a drug its therapeutic effect. Without a reliable API supply chain, the global drug market grinds to a halt.
India is the third-largest producer of APIs globally, holding an 8% share of the global API market. India manufactures over 500 different APIs and accounts for 57% of all APIs on the WHO prequalified list. That prequalification signal means the ingredient meets WHO standards for quality, safety, and manufacturing practice, and it matters enormously to buyers sourcing for public health programs.
India also hosts the largest number of US FDA-approved manufacturing plants outside the United States. The Indian API market was valued at approximately USD 16.86 billion in 2024 and is projected to reach USD 38.13 billion by 2034.
The Active Pharmaceutical Ingredient Backbone
Finished Formulations and Generics
Formulations and biologics account for 79.26% of total pharmaceutical exports by value, according to PHARMEXCIL data. India supplies 20% of global generic drug exports by volume, making it the world’s single largest provider of affordable off-patent medicines. For buyers in the GCC, Southeast Asia, and Africa, this means access to medicines that fit national health budgets without compromising on quality.
Vaccines
India’s vaccine manufacturing scale is extraordinary. As of May 2025, India supplies 55-60% of UNICEF’s total vaccine requirements, including 52% of BCG vaccines and 45% of measles vaccines. This scale comes from decades of investment in biologics manufacturing, cold-chain logistics, and regulatory compliance with WHO standards.
Pharmaceutical Raw Materials
For buyers who manufacture their own formulations, Indian pharmaceutical exporters supply the upstream inputs: bulk drugs, drug intermediates, and APIs across more than 500 molecules. Consolidating raw material sourcing through a single Indian supply partner reduces procurement complexity, cuts lead times, and gives buyers one documentation counterpart instead of many.
New Trade Agreements Opening More Doors
The structural case for sourcing from Indian pharmaceutical exporters just got stronger. Two agreements signed in 2025 are reshaping the cost equation for buyers in Europe and beyond.
The India-UK Comprehensive Economic and Trade Agreement (CETA), signed in July 2025, grants zero-tariff access to nearly all Indian pharmaceutical exports entering the UK market. Indian pharma exports to the UK grew by 12.6% last year even before the agreement came into force.
The India-EFTA Trade and Economic Partnership Agreement, which came into force in October 2025, adds another avenue for Indian pharma exporters to reach European buyers with reduced trade friction.
For B2B buyers in the UK, Europe, GCC, and Southeast Asia, these agreements mean a lower-cost path to sourcing Indian-origin medicines and pharmaceutical ingredients.
The Role of B2B Trading Partners
Not every international buyer has the resources or local knowledge to source directly from Indian manufacturers. Regulatory requirements differ by product category. Manufacturer selection requires technical verification. Documentation for cross-border pharmaceutical trade is detailed and market-specific.
A well-run trading partner does more than place orders. They verify manufacturers, manage compliance documentation, coordinate freight and customs clearance, and serve as a single point of accountability for buyers who need their supply chain to work predictably.
Srindhya Global operates precisely this model. Working with international buyers across the GCC and Southeast Asia, the company sources finished pharmaceuticals, pharma raw materials, and APIs from verified Indian manufacturers and manages the full export process, from sourcing confirmation through delivery and documentation handover. Buyers get the cost advantages of Indian pharmaceutical manufacturing without having to build local sourcing relationships themselves.
The GCC and Southeast Asia are two of the fastest-growing destinations for Indian pharmaceutical exports. GCC health authorities increasingly require WHO-GMP certification from their suppliers, and India’s manufacturing base is well positioned to meet that standard. Across ASEAN, expanding public health programmes and rising per-capita medicine consumption are creating consistent demand for affordable, quality-assured generics.
Where India Is Headed
India’s domestic pharmaceutical market sits at USD 60 billion today and is projected to reach USD 130 billion by 2030. Export growth is expected to track that trajectory, backed by new trade agreements, expanding manufacturing capacity, and rising international demand for affordable generic medicines.
For B2B buyers building long-term supply relationships, the direction of travel is clear. Indian pharmaceutical exporters are a structurally sound sourcing decision backed by regulatory credibility, manufacturing scale, and a government committed to expanding pharmaceutical trade.
FAQS
Have a question before getting in touch? Below are the answers to the queries we hear most often from international B2B buyers. If your question is not covered here, send us a message and our trade team will respond within 24 hours.
Indian pharmaceutical exporters supply finished formulations (tablets, capsules, injectables), active pharmaceutical ingredients (APIs), bulk drugs, drug intermediates, vaccines, and biosimilars. Most exporters cover multiple categories, so international buyers can consolidate sourcing through fewer supplier relationships.
Look for WHO-GMP certification as a baseline for most international markets. For buyers in the United States, US FDA approval is required. European buyers should check for EMA approval and CEP certificates. Your trading partner should confirm the source manufacturer's certifications before any order is placed.
Indian pharmaceutical exports require compliance documentation matched to the destination country's import regulations. This includes certificates of analysis, product registration, and country-specific compliance paperwork. A specialist trading partner like Srindhya Global handles this documentation as part of the export process, removing that burden from the buyer.
India's cost advantage comes from cost-competitive labour, a large domestic chemical industry supplying raw materials, decades of process engineering in generic drug manufacturing, and government policies supporting pharmaceutical export competitiveness. These structural factors keep production costs low without compromising regulatory standards.
Sea freight from Indian ports to GCC destinations generally takes 8-14 days. Shipments to Southeast Asian ports run approximately 10-20 days depending on the destination. Confirm freight timelines with your trading partner at the order stage, not after shipping.